These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

35 related articles for article (PubMed ID: 6230926)

  • 1. Effect of enoximone alone and in combination with metoprolol on myocardial function and energetics in severe congestive heart failure: improvement in hemodynamic and metabolic profile.
    Galie N; Branzi A; Magnani G; Melandri G; Caldarera I; Rapezzi C; Grattoni C; Magnani B
    Cardiovasc Drugs Ther; 1993 Jun; 7(3):337-47. PubMed ID: 8364004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between pharmacokinetics and pharmacodynamics of enoximone in healthy man.
    Belz GG; Meinicke T; Schäfer-Korting M
    Eur J Clin Pharmacol; 1988; 35(6):631-5. PubMed ID: 2976670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of enoximone (MDL-17043) on forearm venous circulation in healthy volunteers and patients with heart failure.
    Branzi A; Berardi C; Ferretti RM; Beato E; Magnani G; Melandri G; Zannoli R; Magnani B
    Heart Vessels; 1987; 3(3):146-51. PubMed ID: 2964430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enoximone: true inotropic effects? Do they cause ischemia? Analysis of end-systolic pressure-volume relations using the conductance (volume) catheter technique.
    Thormann J; Hueting J; Kremer P; Wissemann J; Mitrovic V; Dieterich HA; Schlepper M
    Cardiovasc Drugs Ther; 1990 Oct; 4(5):1403-15. PubMed ID: 2149060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a new 1,3-thiazole derivative ZSY-39 on force of contraction and cyclic AMP content in canine ventricular muscle.
    Endoh M; Satoh H; Norota I; Hirano K
    Cardiovasc Drugs Ther; 1990 Aug; 4(4):1127-34. PubMed ID: 1964579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiischemic and hemodynamic effects of an oral single dose of 150 mg of the phosphodiesterase inhibitor enoximone in patients with coronary artery disease--relation to plasma concentration.
    Mitrovic V; Petrovic O; Bahavar H; Neuzner J; Dieterich HA; Schlepper M
    Cardiovasc Drugs Ther; 1991 Aug; 5(4):689-95. PubMed ID: 1832289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enoximone. A review of its pharmacological properties and therapeutic potential.
    Vernon MW; Heel RC; Brogden RN
    Drugs; 1991 Dec; 42(6):997-1017. PubMed ID: 1724645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term effects of oral enoximone on hemodynamics, exercise capacity, anaerobic threshold, and arrhythmias in congestive heart failure.
    Klauss V; Zwehl W; Mudra H; Huber R; Schmidt R; Scheininger M; Vogler A; Tschaidse O; Dieterich HA; Theisen K
    Klin Wochenschr; 1991 Jul; 69(10):430-5. PubMed ID: 1719270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcellular mechanism of the positive inotropic effect of a new quinolinone derivative OPC-8490 on the dog ventricular myocardium.
    Endoh M; Satoh H; Norota I; Hirano K; Hosokawa T
    Heart Vessels; 1991; 6(3):158-67. PubMed ID: 1655692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status of phosphodiesterase inhibitors in the treatment of congestive heart failure.
    Fischer TA; Erbel R; Treese N
    Drugs; 1992 Dec; 44(6):928-45. PubMed ID: 1282864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations in left ventricular function, coronary hemodynamics and myocardial catecholamine balance with MDL 17043, a new inotropic vasodilator agent, in patients with severe heart failure.
    Viquerat CE; Kereiakes D; Morris DL; Daly PA; Wexman M; Frank P; Parmley WW; Chatterjee K
    J Am Coll Cardiol; 1985 Feb; 5(2 Pt 1):326-32. PubMed ID: 3155761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential mechanisms of improved left ventricular function with enoximone in severe congestive heart failure.
    Chatterjee K; Kereiakes D; Viquerat C; Podolin R
    Am J Cardiol; 1987 Aug; 60(5):37C-41C. PubMed ID: 2956866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role of the enoximone-dobutamine combination in the treatment of congestive cardiac insufficiency].
    Richard C; Thuillez C; Annane D; Bellissant E; Teboul JL
    Arch Mal Coeur Vaiss; 1990 Sep; 83 Spec No 3():33-7. PubMed ID: 2147832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positive inotropic and vasodilator effects of MDL 17,043 in patients with reduced left ventricular performance.
    Crawford MH; Richards KL; Sodums MT; Kennedy GT
    Am J Cardiol; 1984 Apr; 53(8):1051-3. PubMed ID: 6230926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a new cardiotonic agent, MDL-17,043, on myocardial contractility and left ventricular performance in congestive heart failure.
    Strain J; Grose R; Maskin CS; LeJemtel TH
    Am Heart J; 1985 Jul; 110(1 Pt 1):91-6. PubMed ID: 3160228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positive inotropic therapy for short-term support and long-term management of patients with congestive heart failure: hemodynamic effects and clinical efficacy of MDL 17,043.
    Uretsky BF; Valdes AM; Reddy PS
    Circulation; 1986 Mar; 73(3 Pt 2):III219-29. PubMed ID: 2935328
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.